CiMaas

CiMaas is a private, preclinical-stage biotech developing adoptive cell therapies centered on Natural Killer (NK) cells for oncology. Its core technology involves a proprietary feeder cell system (F012) for large-scale expansion of potent, donor-derived NK cells, which can be used alone, combined with therapeutic antibodies, or engineered into CAR-NK products. With a strong scientific advisory board and recent non-dilutive grant funding, the company is translating its platform from preclinical validation into clinical development for a broad range of solid tumors.

Proprietary feeder cell system (F012) using engineered K562 cells expressing membrane-bound IL-21 and 4-1BBL for large-scale expansion of donor-derived Natural Killer (NK) cells, used to create unmodified NK cell therapies, antibody-combination therapies, and CAR-NK cell therapies.

CiMaas competes in the rapidly evolving allogeneic NK and CAR-NK cell therapy arena against companies like Nkarta, Fate Therapeutics, and Century Therapeutics. Its differentiation hinges on its proprietary feeder cell expansion technology and its strategy of combining NK cells with antibody therapies.